Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
0.532 USD | +4.23% | +21.68% | -41.76% |
Mar. 20 | Biggest cyberattacks in US healthcare sector | RE |
Mar. 20 | 23andMe Holding Co. Initiates Phase 1 Clinical Trial for its Dual Mechanism Antibody, 23ME-01473, Targeting ULBP6 | CI |
Financials (USD)
Sales 2024 * | 217M | Sales 2025 * | 265M | Capitalization | 257M |
---|---|---|---|---|---|
Net income 2024 * | - | Net income 2025 * | - | EV / Sales 2024 * | 1.18 x |
Net cash position 2024 * | - | Net cash position 2025 * | - | EV / Sales 2025 * | 0.97 x |
P/E ratio 2024 * |
-0.48
x | P/E ratio 2025 * |
-0.9
x | Employees | 793 |
Yield 2024 * |
-
| Yield 2025 * |
-
| Free-Float | 96.42% |
Latest transcript on 23andMe Holding Co.
1 day | +4.23% | ||
1 week | +21.68% | ||
Current month | -6.67% | ||
1 month | -13.43% | ||
3 months | -42.65% | ||
6 months | -47.84% | ||
Current year | -41.76% |
Managers | Title | Age | Since |
---|---|---|---|
Anne Wojcicki
FOU | Founder | 50 | 05-12-31 |
Joseph Selsavage
DFI | Director of Finance/CFO | 61 | 22-08-31 |
David Baker
CTO | Chief Tech/Sci/R&D Officer | 53 | 19-12-31 |
Members of the board | Title | Age | Since |
---|---|---|---|
Roelof Botha
BRD | Director/Board Member | 50 | 21-06-15 |
Richard Scheller
BRD | Director/Board Member | 70 | 21-06-15 |
Patrick Chung
BRD | Director/Board Member | 50 | 21-06-15 |
Name | Weight | AuM | 1st Jan change | Investor Rating |
---|---|---|---|---|
0.04% | 2 M€ | -.--% | ||
0.02% | 227 M€ | +5.31% | - | |
0.02% | 7 M€ | -.--% | - |
Date | Price | Change | Volume |
---|---|---|---|
24-03-28 | 0.532 | +4.23% | 4,930,623 |
24-03-27 | 0.5104 | +4.63% | 4,852,302 |
24-03-26 | 0.4878 | +8.16% | 6,409,561 |
24-03-25 | 0.451 | +12.33% | 7,467,616 |
24-03-22 | 0.4015 | -8.17% | 6,066,467 |
Delayed Quote Nasdaq, March 28, 2024 at 04:00 pm EDT
More quotesEPS Revisions
1st Jan change | Capi. | |
---|---|---|
-41.76% | 257M | |
-8.32% | 9.21B | |
-9.54% | 3.67B | |
+39.95% | 3.59B | |
-4.12% | 2.6B | |
-12.21% | 2.25B | |
-2.84% | 2.01B | |
-16.85% | 1.63B | |
-25.37% | 1.54B | |
-7.98% | 1.12B |